Mechanisms of human papillomavirus type 16 neutralization by L2 cross-neutralizing and L1 type-specific antibodies

被引:134
作者
Day, Patricia M. [1 ]
Garnbhira, Ratish [2 ]
Roden, Richard B. S. [2 ]
Lowy, Douglas R. [1 ]
Schiller, John T. [1 ]
机构
[1] NIH, Cellular Oncol Lab, Natl Canc Inst, Bethesda, MD 20892 USA
[2] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA
关键词
D O I
10.1128/JVI.00143-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Pseudovirions of human papillomavirus type 16 (HPV16), the principal etiologic agent in 50% of cervical cancers, were used as a model system to investigate the cell surface interactions involved in the exposure of the broadly cross-neutralizing papillomavirus L2 epitopes. These neutralizing epitopes were exposed only after cell surface binding and a subsequent change in capsid conformation that permitted cleavage by the cellular protease furin at a specific highly conserved site in L2 that is immediately upstream of the cross-neutralizing epitopes. Unexpectedly, binding of L2 antibodies led to the release of the capsid/antibody complexes from the cell surface and their accumulation on the extracellular matrix. Study of the dynamics of exposure of the L2 epitopes further revealed that representatives of the apparently dominant class of L1-specific neutralizing antibodies induced by virus-like particle vaccination prevent infection, not by preventing cell surface binding but rather by preventing the conformation change involved in exposure of the L2 neutralizing epitope. These findings suggest a dynamic model of virion-cell surface interactions that has implications for both evolution of viral serotypes and the efficacy of current and future HPV vaccines.
引用
收藏
页码:4638 / 4646
页数:9
相关论文
共 38 条
[1]   The influence of virus structure on antibody responses and virus serotype formation [J].
Bachmann, MF ;
Zinkernagel, RM .
IMMUNOLOGY TODAY, 1996, 17 (12) :553-558
[2]   Crystal structures of four types of human papillomavirus L1 capsid - Understanding the specificity of neutralizing monoclonal antibodies [J].
Bishop, Brooke ;
Dasgupta, Jhimli ;
Klein, Michael ;
Garcea, Robert L. ;
Christensen, Neil D. ;
Zhao, Rui ;
Chen, Xiaojiang S. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (43) :31803-31811
[3]   Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection [J].
Bossis, L ;
Roden, RBS ;
Gambhira, R ;
Yang, R ;
Tagaya, M ;
Howley, PA ;
Meneses, PI .
JOURNAL OF VIROLOGY, 2005, 79 (11) :6723-6731
[4]   Maturation of papillomavirus capsids [J].
Buck, CB ;
Thompson, CD ;
Pang, YYS ;
Lowy, DR ;
Schiller, JT .
JOURNAL OF VIROLOGY, 2005, 79 (05) :2839-2846
[5]   Solid supports in enzyme-linked immunosorbent assay and other solid-phase immunoassays [J].
Butler, JE .
METHODS-A COMPANION TO METHODS IN ENZYMOLOGY, 2000, 22 (01) :4-23
[6]   Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies [J].
Christensen, ND ;
Dillner, J ;
Eklund, C ;
Carter, JJ ;
Wipf, GC ;
Reed, CA ;
Cladel, NM ;
Galloway, DA .
VIROLOGY, 1996, 223 (01) :174-184
[7]   Human papillomaviruses bind a basal extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated receptor [J].
Culp, TD ;
Budgeon, LR ;
Christensen, ND .
VIROLOGY, 2006, 347 (01) :147-159
[8]   Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition [J].
Day, Patricia M. ;
Thompson, Cynthia D. ;
Buck, Christopher B. ;
Pang, Yuk-Ying S. ;
Lowy, Douglas R. ;
Schiller, John T. .
JOURNAL OF VIROLOGY, 2007, 81 (16) :8784-8792
[9]   Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression [J].
Day, PM ;
Baker, CC ;
Lowy, DR ;
Schiller, JT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (39) :14252-14257
[10]   Papillomaviruses infect cells via a clathrin-dependent pathway [J].
Day, PM ;
Lowy, DR ;
Schiller, JT .
VIROLOGY, 2003, 307 (01) :1-11